Today: 18 April 2026
NuScale Power Stock Jumps as Fluor’s $150 Million SMR Share Sale Lands
18 April 2026
2 mins read

NuScale Power Stock Jumps as Fluor’s $150 Million SMR Share Sale Lands

NEW YORK, April 18, 2026, 13:41 (EDT)

  • Fluor unloaded 12.9 million shares of NuScale Power to Citi, pricing each at $11.6293, according to an SEC filing.
  • Fluor’s reported stake in NuScale dropped to 3.9% after the sale, sliding under the 5% threshold for Schedule 13D disclosure.
  • NuScale finished Friday at $12.65, climbing roughly 10.8% as volume surged.

NuScale Power Corp. jumped Friday, despite filings revealing that Fluor Corp., a long-term supporter, unloaded 12.9 million shares in the company for roughly $150.4 million.

The sale takes on fresh significance, dropping Fluor’s reported NuScale position under the 5% threshold and effectively lifting a disclosure requirement that’s lingered through its efforts to cash out. For large shareholders, Schedule 13D filings flag both ownership and intentions; with this latest move, Fluor said it’s off the hook for further filings tied to NuScale.

NuScale finished Friday at $12.65, climbing roughly 10.8% as nearly 67.1 million shares changed hands. The jump for the advanced nuclear player landed amid a choppy stretch for the sector, with traders toggling between optimism over rising power demand and nagging worries about funding, project delays, and possible dilution.

Fluor’s subsidiary unloaded 12,936,472 NuScale Class A shares at $11.6293 apiece on April 15, a Form 4 shows. The document, signed April 17 by chief legal officer and corporate secretary Kevin B. Hammonds, notes the sale came under a previously disclosed agreement.

An updated filing identified Citibank, N.A. as the purchaser, citing a February letter agreement involving Nuke Holdings—a Fluor subsidiary—and Citigroup Global Markets, which served as collateral custodian. According to the filing, Fluor’s leftover stake in NuScale stood at 13.5 million shares, amounting to 3.9% of the combined Class A and Class B stock.

Back in February, Fluor told investors it pocketed $1.35 billion from unloading 71 million NuScale shares, and said it was working on cashing out its last 40 million shares, a process it expects to wrap up in the second quarter of 2026.

This sale stems from an agreement struck last November, when Fluor and NuScale decided to convert and unload Fluor’s final stake. Back then, Fluor CEO Jim Breuer described the NuScale position as a “successful investment.” John Hopkins, who heads NuScale, framed Fluor’s departure as just a “natural evolution” in how the companies work together. Fluor Investor Relations

NuScale is focused on small modular reactors, known as SMRs—nuclear units built in factories, shipped out, and then assembled in modules instead of as a single massive facility. According to the company, each NuScale Power Module puts out 77 megawatts of electricity. String together 12 modules, and total output climbs to 924 megawatts.

Action was steady across the competitive set. Shares of Oklo, an advanced nuclear developer, finished Friday up roughly 4.0%. Nano Nuclear Energy climbed around 5.5%, market data showed.

Still, Fluor’s move leaves NuScale facing its toughest challenge: locking in firm customer agreements—and figuring out if project financing can land at a price point utilities and big industrials will tolerate. Last year, Reuters reported NuScale’s flagship U.S. SMR initiative with a Utah municipal power group was scrapped in 2023, citing cost blowouts, despite federal funding already secured.

NuScale retains a regulatory edge for now. The U.S. Nuclear Regulatory Commission signed off on its 77-megawatt reactor design in May 2025. Hopkins, speaking to Reuters at the time, called the approval a milestone that put the technology “near-term deployable”—though he emphasized that rollout would depend on customer timelines. Reuters

NuScale’s next update lands soon. The company will go over first-quarter 2026 results on May 7 at 5:00 p.m. ET, offering investors new details on cash burn, recent commercial moves, and any shifts in its project pipeline since Fluor trimmed its stake.

Stock Market Today

  • Is Iovance Biotherapeutics (IOVA) Share Price Reflecting Its True Value Amid Strong Gains?
    April 18, 2026, 1:54 PM EDT. Iovance Biotherapeutics (IOVA) has surged 50.8% year-to-date, but its long-term returns remain negative. The stock trades at $3.80, significantly below its $23.22 intrinsic value estimated by a discounted cash flow (DCF) model, suggesting it is undervalued by 83.6%. The DCF projects free cash flow turning positive by 2030, backing optimism despite recent losses. Investors face a mixed picture: strong recent gains clash with a multi-year decline. Valuation models indicate the market may not have fully priced in Iovance's growth potential, prompting debate over the stock's risk and future prospects amid evolving investor sentiment.

Latest article

US Stock Market Hits Record Highs — But Monday’s Open Now Depends on Hormuz

US Stock Market Hits Record Highs — But Monday’s Open Now Depends on Hormuz

18 April 2026
U.S. stocks closed at record highs Friday, with the S&P 500 and Nasdaq logging their third straight records as oil prices plunged and hopes rose for a U.S.-Iran deal. Brent crude fell 9% to $90.38 a barrel after Iran said ships could pass the Strait of Hormuz, but by Saturday Iran tightened control and ships reported gunfire. The Dow jumped 868.71 points to 49,447.43. Energy stocks lagged as travel and consumer shares surged.
Grab Holdings Limited Stock Jumps Before Earnings as Buyback and Taiwan Deal Face a Hard Test
Previous Story

Grab Holdings Limited Stock Jumps Before Earnings as Buyback and Taiwan Deal Face a Hard Test

Go toTop